Brokerages Anticipate Cytosorbents Corp (NASDAQ:CTSO) to Announce -$0.17 EPS
Analysts expect Cytosorbents Corp (NASDAQ:CTSO) to post earnings per share of ($0.17) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Cytosorbents’ earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.23). Cytosorbents also reported earnings of ($0.17) per share during the same quarter last year. The firm is scheduled to issue its next earnings report on Thursday, March 5th.
According to Zacks, analysts expect that Cytosorbents will report full year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.70) to ($0.51). For the next year, analysts anticipate that the company will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.66) to ($0.08). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.08). The firm had revenue of $6.10 million for the quarter, compared to analysts’ expectations of $6.49 million. Cytosorbents had a negative net margin of 87.79% and a negative return on equity of 165.00%.
Shares of Cytosorbents stock traded up $0.35 during trading hours on Friday, reaching $3.96. The stock had a trading volume of 457,600 shares, compared to its average volume of 152,763. The firm has a market capitalization of $124.18 million, a price-to-earnings ratio of -7.07 and a beta of 1.65. Cytosorbents has a 1 year low of $3.49 and a 1 year high of $9.82. The company has a current ratio of 2.40, a quick ratio of 2.21 and a debt-to-equity ratio of 1.88. The firm has a 50 day simple moving average of $4.44 and a two-hundred day simple moving average of $5.53.
In related news, CEO Phillip P. Chan purchased 16,500 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was purchased at an average cost of $3.96 per share, for a total transaction of $65,340.00. 5.60% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Cadence Capital Management LLC acquired a new position in shares of Cytosorbents during the third quarter worth about $61,000. D. E. Shaw & Co. Inc. acquired a new stake in shares of Cytosorbents in the second quarter valued at about $164,000. Advisor Group Inc. grew its stake in shares of Cytosorbents by 15.8% in the second quarter. Advisor Group Inc. now owns 33,170 shares of the medical research company’s stock valued at $219,000 after buying an additional 4,530 shares in the last quarter. Susquehanna International Group LLP raised its holdings in shares of Cytosorbents by 933.4% during the 2nd quarter. Susquehanna International Group LLP now owns 38,447 shares of the medical research company’s stock valued at $254,000 after buying an additional 43,060 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Cytosorbents by 31.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 81,270 shares of the medical research company’s stock valued at $538,000 after buying an additional 19,439 shares during the period. Institutional investors own 26.06% of the company’s stock.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
See Also: Buy-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.